Pulmonx (LUNG) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LUNG Stock Forecast

Pulmonx stock forecast is as follows: an average price target of $13.00 (represents a 107.83% upside from LUNG’s last price of $6.25) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

LUNG Price Target

The average price target for Pulmonx (LUNG) is $13.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $16.00 to $10.00. This represents a potential 107.83% upside from LUNG's last price of $6.25.

LUNG Analyst Ratings

Buy

According to 5 Wall Street analysts, Pulmonx's rating consensus is 'Buy'. The analyst rating breakdown for LUNG stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pulmonx Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 31, 2024	Jason Bednar	Piper Sandler	$10.00	$6.79	47.28%	59.87%
Aug 01, 2024	William Plovanic	Canaccord Genuity	$16.00	$7.42	115.63%	155.80%
Jun 04, 2024	Frank Takkinen	Loop Capital Markets	$12.00	$7.00	71.43%	91.85%
Jan 06, 2023		Morgan Stanley	$9.50	$7.88	20.56%	51.88%
Dec 12, 2022		Wells Fargo	$6.00	$6.22	-3.54%	-4.08%
Dec 12, 2022		Citigroup	$10.00	$5.88	70.07%	59.87%
Jul 18, 2022		Stifel Nicolaus	$20.00	$16.37	22.17%	219.74%
Jul 15, 2022		Morgan Stanley	$19.00	$16.20	17.25%	203.76%

The latest Pulmonx stock forecast, released on Oct 31, 2024 by Jason Bednar from Piper Sandler, set a price target of $10.00, which represents a 47.28% increase from the stock price at the time of the forecast ($6.79), and a 59.87% increase from LUNG last price ($6.25).

Pulmonx Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	3
Avg Price Target	-	$10.00	$12.67
Last Closing Price	$6.25	$6.25	$6.25
Upside/Downside	-100.00%	59.87%	102.56%

In the current month, the average price target of Pulmonx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pulmonx's last price of $6.25. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 11, 2024	Citigroup	Buy	Neutral	Downgrade
Oct 31, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 04, 2024	Lake Street		Buy	Initialise
Apr 03, 2024	Wells Fargo	Buy	Buy	Hold
Feb 27, 2023	Wells Fargo	Equal-Weight	Overweight	Upgrade
Jan 06, 2023	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Dec 12, 2022	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Dec 12, 2022	Citigroup		Buy	Upgrade
Jul 15, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Feb 25, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Feb 24, 2022	Wells Fargo	Equal-Weight	Equal-Weight	Hold

Pulmonx's last stock rating was published by Citigroup on Dec 11, 2024. The company Downgrade its LUNG rating from "Buy" to "Neutral".

Pulmonx Financial Forecast

Pulmonx Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.67M	$17.19M	$14.54M	$15.43M	$13.50M	$13.95M	$10.79M	$13.71M	$13.26M	$12.20M	$9.24M	$9.83M	$10.61M
Avg Forecast	$29.20M	$28.20M	$28.20M	$25.20M	$26.48M	$24.16M	$24.77M	$22.23M	$22.29M	$20.29M	$20.15M	$18.03M	$18.24M	$16.67M	$15.86M	$13.49M	$13.98M	$14.93M	$13.77M	$9.26M	$14.24M	$13.18M	$10.59M	$8.18M	$8.81M	$7.96M
High Forecast	$30.07M	$29.04M	$29.04M	$25.95M	$27.27M	$24.87M	$25.51M	$22.64M	$22.43M	$20.29M	$20.15M	$18.03M	$18.47M	$17.90M	$16.33M	$13.89M	$14.39M	$14.93M	$13.77M	$9.26M	$14.24M	$13.18M	$10.59M	$8.18M	$8.81M	$7.96M
Low Forecast	$28.01M	$27.05M	$27.05M	$24.17M	$25.40M	$23.17M	$23.76M	$21.81M	$22.14M	$20.29M	$20.15M	$18.03M	$18.01M	$16.20M	$15.21M	$12.94M	$13.41M	$14.93M	$13.77M	$9.26M	$14.24M	$13.18M	$10.59M	$8.18M	$8.81M	$7.96M
# Analysts	2	2	2	2	1	1	1	4	4	2	1	1	2	5	4	4	3	3	3	3	4	4	4	4	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.06%	1.08%	1.08%	1.10%	0.90%	1.01%	1.16%	0.96%	1.01%	1.15%	1.13%	1.12%	1.33%

Pulmonx's average Quarter revenue forecast for Dec 23 based on 2 analysts is $18.24M, with a low forecast of $18.01M, and a high forecast of $18.47M. LUNG's average Quarter revenue forecast represents a 3.26% increase compared to the company's last Quarter revenue of $17.67M (Sep 23).

Pulmonx EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	1	1	1	4	4	2	1	1	2	5	4	4	3	3	3	3	4	4	4	4	4	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-13.95M	$-15.19M	$-15.16M	$-13.68M	$-13.89M	$-14.38M	$-15.56M	$-12.28M	$-9.72M	$-11.95M	$-11.62M	$-8.88M	$-2.59M
Avg Forecast	$-24.24M	$-23.41M	$-23.41M	$-20.92M	$-21.98M	$-20.05M	$-20.56M	$-18.45M	$-18.50M	$-16.84M	$-16.72M	$-20.37M	$-15.14M	$-13.83M	$-13.16M	$-16.10M	$-13.88M	$-12.77M	$-11.78M	$-12.73M	$-12.18M	$-11.27M	$-9.05M	$-12.84M	$-7.53M	$-3.92M
High Forecast	$-23.25M	$-22.45M	$-22.45M	$-20.06M	$-21.08M	$-19.23M	$-19.72M	$-18.10M	$-18.38M	$-16.84M	$-16.72M	$-16.30M	$-14.94M	$-13.44M	$-12.63M	$-12.88M	$-11.11M	$-12.77M	$-11.78M	$-10.18M	$-12.18M	$-11.27M	$-9.05M	$-10.27M	$-7.53M	$-3.13M
Low Forecast	$-24.96M	$-24.10M	$-24.10M	$-21.54M	$-22.63M	$-20.65M	$-21.17M	$-18.79M	$-18.62M	$-16.84M	$-16.72M	$-24.45M	$-15.33M	$-14.85M	$-13.55M	$-19.33M	$-16.66M	$-12.77M	$-11.78M	$-15.28M	$-12.18M	$-11.27M	$-9.05M	$-15.41M	$-7.53M	$-4.70M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.15%	0.94%	0.99%	1.09%	1.22%	1.22%	1.01%	0.86%	1.32%	0.90%	1.18%	0.66%

undefined analysts predict LUNG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pulmonx's previous annual EBITDA (undefined) of $NaN.

Pulmonx Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	1	1	1	4	4	2	1	1	2	5	4	4	3	3	3	3	4	4	4	4	4	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.90M	$-16.20M	$-15.86M	$-14.28M	$-13.79M	$-14.64M	$-15.83M	$-13.01M	$-10.18M	$-12.38M	$-12.04M	$-9.30M	$-3.86M
Avg Forecast	$-13.75M	$-14.53M	$-14.53M	$-16.89M	$-15.95M	$-15.28M	$-15.78M	$-15.52M	$-17.17M	$-17.62M	$-16.66M	$-21.22M	$-15.43M	$-16.81M	$-17.14M	$-16.78M	$-14.70M	$-15.44M	$-15.96M	$-13.26M	$-14.03M	$-14.49M	$-14.48M	$-13.31M	$-10.83M	$-5.85M
High Forecast	$-13.02M	$-13.76M	$-13.76M	$-15.99M	$-15.10M	$-14.47M	$-14.95M	$-14.68M	$-16.37M	$-16.68M	$-15.78M	$-16.98M	$-15.21M	$-15.63M	$-16.23M	$-13.42M	$-11.76M	$-15.44M	$-15.96M	$-10.61M	$-14.03M	$-14.49M	$-14.48M	$-10.65M	$-10.83M	$-4.68M
Low Forecast	$-14.28M	$-15.09M	$-15.09M	$-17.54M	$-16.56M	$-15.87M	$-16.39M	$-16.36M	$-17.57M	$-18.30M	$-17.31M	$-25.47M	$-15.65M	$-18.37M	$-17.80M	$-20.13M	$-17.64M	$-15.44M	$-15.96M	$-15.91M	$-14.03M	$-14.49M	$-14.48M	$-15.98M	$-10.83M	$-7.02M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.89%	0.94%	0.95%	0.97%	0.89%	0.92%	1.19%	0.93%	0.70%	0.85%	0.90%	0.86%	0.66%

Pulmonx's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LUNG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Pulmonx SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	1	1	1	4	4	2	1	1	2	5	4	4	3	3	3	3	4	4	4	4	4	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$23.98M	$23.46M	$22.74M	$21.91M	$19.72M	$21.23M	$20.25M	$18.91M	$16.69M	$17.62M	$15.60M	$13.96M	$10.81M
Avg Forecast	$39.87M	$38.50M	$38.50M	$34.40M	$36.15M	$32.98M	$33.82M	$30.34M	$30.43M	$27.70M	$27.50M	$24.62M	$24.91M	$22.75M	$21.65M	$18.42M	$19.08M	$20.37M	$18.78M	$12.63M	$19.43M	$17.97M	$14.44M	$11.16M	$12.01M	$10.86M
High Forecast	$41.05M	$39.64M	$39.64M	$35.43M	$37.23M	$33.96M	$34.82M	$30.92M	$30.62M	$27.70M	$27.50M	$24.62M	$25.22M	$24.43M	$22.30M	$18.97M	$19.65M	$20.37M	$18.78M	$12.63M	$19.43M	$17.97M	$14.44M	$11.16M	$12.01M	$10.86M
Low Forecast	$38.24M	$36.93M	$36.93M	$33.00M	$34.68M	$31.64M	$32.44M	$29.77M	$30.23M	$27.70M	$27.50M	$24.62M	$24.58M	$22.12M	$20.77M	$17.67M	$18.31M	$20.37M	$18.78M	$12.63M	$19.43M	$17.97M	$14.44M	$11.16M	$12.01M	$10.86M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.05%	1.08%	1.23%	1.15%	0.97%	1.13%	1.60%	0.97%	0.93%	1.22%	1.40%	1.16%	1.00%

Pulmonx's average Quarter SG&A projection for Dec 23 is $24.91M, based on 2 Wall Street analysts, with a range of $24.58M to $25.22M. The forecast indicates a 3.85% rise compared to LUNG last annual SG&A of $23.98M (Sep 23).

Pulmonx EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	1	1	1	4	4	2	1	1	2	5	4	4	3	3	3	3	4	4	4	4	4	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.39	$-0.43	$-0.42	$-0.38	$-0.37	$-0.40	$-0.43	$-0.35	$-0.28	$-0.34	$-0.34	$-0.27	$-0.13
Avg Forecast	$-0.35	$-0.37	$-0.37	$-0.43	$-0.41	$-0.39	$-0.40	$-0.40	$-0.44	$-0.45	$-0.42	$-0.47	$-0.39	$-0.43	$-0.44	$-0.44	$-0.42	$-0.40	$-0.41	$-0.37	$-0.36	$-0.37	$-0.37	$-0.39	$-0.28	$-5.33
High Forecast	$-0.33	$-0.35	$-0.35	$-0.41	$-0.38	$-0.37	$-0.38	$-0.37	$-0.42	$-0.42	$-0.40	$-0.44	$-0.39	$-0.40	$-0.41	$-0.42	$-0.39	$-0.40	$-0.41	$-0.37	$-0.36	$-0.37	$-0.37	$-0.39	$-0.28	$-5.33
Low Forecast	$-0.36	$-0.38	$-0.38	$-0.45	$-0.42	$-0.40	$-0.42	$-0.42	$-0.45	$-0.47	$-0.44	$-0.49	$-0.40	$-0.47	$-0.45	$-0.46	$-0.43	$-0.40	$-0.41	$-0.37	$-0.36	$-0.37	$-0.37	$-0.39	$-0.28	$-5.33
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.99%	0.95%	0.91%	0.93%	0.98%	1.16%	0.97%	0.75%	0.91%	0.87%	0.97%	0.02%

According to undefined Wall Street analysts, Pulmonx's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LUNG previous annual EPS of $NaN (undefined).

Pulmonx Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
APYX	Apyx Medical	$1.64	$8.50	418.29%	Buy
INGN	Inogen	$9.12	$26.00	185.09%	Buy
LUNG	Pulmonx	$6.13	$13.00	112.07%	Buy
RXST	RxSight	$38.04	$70.14	84.38%	Buy
KIDS	OrthoPediatrics	$22.46	$39.50	75.87%	Buy
LIVN	LivaNova	$49.94	$68.25	36.66%	Buy
CNMD	CONMED	$71.23	$97.00	36.18%	Buy
OFIX	Orthofix Medical	$17.93	$24.00	33.85%
SIBN	SI-BONE	$13.84	$18.50	33.67%	Buy
NPCE	NeuroPace	$11.52	$15.00	30.21%	Buy
IRMD	IRadimed	$53.00	$60.00	13.21%	Buy
ITGR	Integer	$136.68	$153.50	12.31%	Buy
SRDX	Surmodics	$39.96	$39.50	-1.15%	Buy

LUNG Forecast FAQ

Is Pulmonx a good buy?

Yes, according to 5 Wall Street analysts, Pulmonx (LUNG) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of LUNG's total ratings.

What is LUNG's price target?

Pulmonx (LUNG) average price target is $13 with a range of $10 to $16, implying a 107.83% from its last price of $6.25. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pulmonx stock go up soon?

According to Wall Street analysts' prediction for LUNG stock, the company can go up by 107.83% (from the last price of $6.25 to the average price target of $13), up by 155.80% based on the highest stock price target, and up by 59.87% based on the lowest stock price target.

Can Pulmonx stock reach $9?

LUNG's average twelve months analyst stock price target of $13 supports the claim that Pulmonx can reach $9 in the near future.

What are Pulmonx's analysts' financial forecasts?

Pulmonx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $97.63M (high $100.29M, low $94.14M), average EBITDA is $-81.035M (high $-78.136M, low $-83.243M), average net income is $-62.533M (high $-59.202M, low $-65.189M), average SG&A $133.29M (high $136.93M, low $128.53M), and average EPS is $-1.592 (high $-1.507, low $-1.66). LUNG's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $110.8M (high $114.09M, low $106.28M), average EBITDA is $-91.964M (high $-88.214M, low $-94.698M), average net income is $-59.7M (high $-56.536M, low $-62.007M), average SG&A $151.27M (high $155.77M, low $145.1M), and average EPS is $-1.52 (high $-1.439, low $-1.579).

Did the LUNG's actual financial results beat the analysts' financial forecasts?

Based on Pulmonx's last annual report (Dec 2023), the company's revenue was $68.68M, beating the average analysts forecast of $64.26M by 6.86%. Apple's EBITDA was $-61.935M, beating the average prediction of $-58.244M by 6.34%. The company's net income was $-60.843M, missing the average estimation of $-66.146M by -8.02%. Apple's SG&A was $94.61M, beating the average forecast of $87.74M by 7.83%. Lastly, the company's EPS was $-0.0016, missing the average prediction of $-1.697 by -99.91%. In terms of the last quarterly report (Sep 2023), Pulmonx's revenue was $17.67M, beating the average analysts' forecast of $16.67M by 6.01%. The company's EBITDA was $-13.948M, beating the average prediction of $-13.833M by 0.83%. Pulmonx's net income was $-14.9M, missing the average estimation of $-16.807M by -11.35%. The company's SG&A was $23.98M, beating the average forecast of $22.75M by 5.41%. Lastly, the company's EPS was $-0.39, missing the average prediction of $-0.428 by -8.86%